IGF 1 lr3 as we know is a fantastic growth factor for bodybuilders and athletes of all kinds. Used for Building quality lean muscle mass, as well as for its ability to keep you lean by way of signa;ling the body to burn fat for energy. We have also read and posted many studies here at MuscleChemistry regarding Insulin-like growth factor 1 healing power and regenerative capabilities on tendons and cartlidge and it promotes collagen synthesis as well. But lately I have been reading a ton on IGF 1 treatment for Central Nervous System Disorders.

So Enjoy:

The therapeutic potential of IGF-1 was found to be relevant to the treatment of several CNS disorders, most notably Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, and autism spectrum disorder. Table 1 categorizes the human clinical trials in specific CNS diseases.
Table 1

Clinical Trials with IGF-1 in CNS DisordersOverview of clinical trials using IGF-1 as a therapeutic agent in CNS disorders to date

Intervention Author
and Year
Sample
Size
Study
Design
Duration
of
Treatment
Primary
Outcome
Measure
Outcome
Multiple
Sclerosis
rhIGF-1 (J. A. Frank et al., 2002) 7 Open-label
crossover
6 months Contrast
enhancing lesion
frequency on
MRI
Negative
Amyotrophic
Lateral
Sclerosis
rhIGF-1 (Nagano, Shiote, et al., 2005) 9 Double-
blind,
randomized
clinical
9 months Norris Scales Positive
Amyotrophic
Lateral
Sclerosis
rhIGF-1 (Lai et al., 1997) 141 Double
blind,
placebo
controlled,
parallel
group
9 months Appel
Amyotrophic
Lateral Sclerosis
rating scale
Positive
Amyotrophic
Lateral
Sclerosis
rhIGF-1 (Borasio et al., 1998) 183 Double
blind,
placebo
controlled,
parallel
group
9 months Appel
Amyotrophic
Lateral Sclerosis
rating scale
Negative
Amyotrophic
Lateral
Sclerosis
rhIGF-1 (Sorenson et al., 2008) 330 Double
blind,
placebo
controlled,
parallel
group
2 years Rate of change
in the averaged
manual muscle
testing score
(MMT)
Negative
Alzheimer’s
Dementia
MK-677 (Sevigny et al., 2008) 563 Double
blind,
placebo
controlled,
parallel
group
12 months Clinician’s
Interview Based
Impression of
Change with
caregiver input
(CIBIC-plus)
Negative
Phelan-
McDermid
syndrome
rhIGF-1 (Kolevzon et al., 2014) 9 Double
blind,
placebo
controlled,
crossover
3 months Aberrant
Behavior
Checklist-Social
Withdrawal
subscale
Positive
Rett
syndrome
rhIGF-1 (Khwaja et al., 2014) 9
(MAD)
12
(OLE)
Unblind
multiple
ascending
dose and
open label
extension
4 week
MAD
20 week
OLE
Multiple
Cardiorespiratory
measures
Positive

Open in a separate window
Abbreviations: MK-677 = ibutamoren mesylate; MAD = multiple ascending dose; OLE = open-label extension






The extensive investigation of the effect of IGF-1 during development and the continued discovery of its diverse roles throughout the CNS exemplifies the presence of common underlying pathways responsible for neuronal development. Although many different genetic mutations and disrupted pathways lead to syndromes associated with ASD, there is significant overlap in their molecular and electrophysiological deficits. Specific deficits in synaptic function and plasticity in glutamate signaling have been consistently documented in various forms of ASD using mouse and human neuronal models and have been rescued with IGF-1. The link between synapse dysfunction and ASD suggest that treatment with IGF-1 may also have implications for ASD associated with disruptions in common underlying pathways. Preliminary studies in children with PMS and Rett syndrome have been successful, and IGF-1 may also be a promising therapeutic candidate in other single gene causes of ASD and perhaps in idiopathic ASD; a trial is underway with IGF-1 in ASD defined broadly (ClinicalTrials.gov Identifier: NCT01970345). Although definitive studies are needed, pilot data suggest the promise of IGF-1 in neurodevelopmental disorders associated with ASD.

Highlights

  • IGF-1 is necessary for proper development of the central nervous system
  • IGF-1 dysregulation leads to neuronal dysfunction and severe developmental disorders
  • IGF-1 may be a safe and potentially effective treatment for several CNS disorders